SEC Form SCHEDULE 13G filed by CeriBell Inc.
$CBLL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Ceribell, Inc. (Name of Issuer) |
Common Stock, $0.001 par value per share (Title of Class of Securities) |
15678C102 (CUSIP Number) |
12/31/2024 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
| Rule 13d-1(c)
|
 Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG WTT-Ceribell Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG V-Ceribell Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG V-Ceribell Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
Ally Bridge Group Global Life Science Capital Partners V, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: Ally Bridge Group Global Life Science Capital Partners V, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG Global Life Science Capital Partners V GP, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: ABG Global Life Science Capital Partners V GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG Global Life Science Capital Partners V GP Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG Global Life Science Capital Partners V GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG-WTT Global Life Science Capital Partners GP, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person: ABG-WTT Global Life Science Capital Partners GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG-WTT Global Life Science Capital Partners GP Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG-WTT Global Life Science Capital Partners GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
ABG Management Ltd. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: ABG Management Ltd. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
Ally Bridge Group (PE) LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IA, OO |
Comment for Type of Reporting Person: Ally Bridge Group (PE) LLC is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| CUSIP No. | 15678C102 |
| 1 | Names of Reporting Persons
Fan Yu | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
MALTA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,441,267.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: Fan Yu is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.
The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Ceribell, Inc. | |
| (b) | Address of issuer's principal executive offices:
360 N. Pastoria Avenue, Sunnyvale, California 94085 | |
| Item 2. | ||
| (a) | Name of person filing:
This Schedule 13G is jointly filed, pursuant to a Joint Filing Agreement attached hereto as Exhibit 1
ABG WTT-Ceribell Limited
ABG V-Ceribell Limited
Ally Bridge Group Global Life Science Capital Partners V, L.P.
ABG Global Life Science Capital Partners V GP, L.P.
ABG Global Life Science Capital Partners V GP Limited
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
ABG-WTT Global Life Science Capital Partners GP, L.P.
ABG-WTT Global Life Science Capital Partners GP Limited
ABG Management Ltd.
Ally Bridge Group (PE) LLC
Fan Yu | |
| (b) | Address or principal business office or, if none, residence:
ABG WTT-Ceribell Limited
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG V-Ceribell Limited
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
Ally Bridge Group Global Life Science Capital Partners V, L.P
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG Global Life Science Capital Partners V GP, L.P.
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG Global Life Science Capital Partners V GP Limited
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG-WTT Global Life Science Capital Partners GP, L.P.
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG-WTT Global Life Science Capital Partners GP Limited
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
ABG Management Ltd.
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104
Ally Bridge Group (PE) LLC
430 Park Avenue
New York, New York 10022
United States of America
Fan Yu
c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104 | |
| (c) | Citizenship:
ABG WTT-Ceribell Limited - Cayman Islands
ABG V-Ceribell Limited - Cayman Islands
Ally Bridge Group Global Life Science Capital Partners V, L.P. - Cayman Islands
ABG Global Life Science Capital Partners V GP, L.P. - Cayman Islands
ABG Global Life Science Capital Partners V GP Limited - Cayman Islands
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - Cayman Islands
ABG-WTT Global Life Science Capital Partners GP, L.P. - Cayman Islands
ABG-WTT Global Life Science Capital Partners GP Limited - Cayman Islands
ABG Management Ltd.- Cayman Islands
Ally Bridge Group (PE) LLC - Delaware
Fan Yu - Malta | |
| (d) | Title of class of securities:
Common Stock, $0.001 par value per share | |
| (e) | CUSIP No.:
15678C102 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
ABG WTT-Ceribell Limited: 2,441,267
ABG V-Ceribell Limited: 2,441,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP Limited: 2,441,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.: 2,441,267
ABG-WTT Global Life Science Capital Partners GP, L.P.: 2,441,267
ABG-WTT Global Life Science Capital Partners GP Limited: 2,441,267
ABG Management Ltd.: 2,441,267
Ally Bridge Group (PE) LLC: 2,441,267
Fan Yu: 2,441,267 | |
| (b) | Percent of class:
ABG WTT-Ceribell Limited: 6.8%
ABG V-Ceribell Limited: 6.8%
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 6.8%
ABG Global Life Science Capital Partners V GP, L.P. : 6.8%
ABG Global Life Science Capital Partners V GP Limited: 6.8%
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 6.8%
ABG-WTT Global Life Science Capital Partners GP, L.P.: 6.8%
ABG-WTT Global Life Science Capital Partners GP Limited: 6.8%
ABG Management Ltd.: 6.8%
Ally Bridge Group (PE) LLC: 6.8%
Fan Yu: 6.8% | |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
ABG WTT-Ceribell Limited: 0
ABG V-Ceribell Limited: 0
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0
ABG Global Life Science Capital Partners V GP, L.P. : 0
ABG Global Life Science Capital Partners V GP Limited: 0
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0
ABG-WTT Global Life Science Capital Partners GP, L.P.: 0
ABG-WTT Global Life Science Capital Partners GP Limited: 0
ABG Management Ltd.: 0
Ally Bridge Group (PE) LLC: 0
Fan Yu: 0 | ||
| (ii) Shared power to vote or to direct the vote:
ABG WTT-Ceribell Limited: 2,441,267
ABG V-Ceribell Limited: 2,441,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP Limited: 2,441,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 2,441,267
ABG-WTT Global Life Science Capital Partners GP, L.P.: 2,441,267
ABG-WTT Global Life Science Capital Partners GP Limited: 2,441,267
ABG Management Ltd.: 2,441,267
Ally Bridge Group (PE) LLC: 2,441,267
Fan Yu: 2,441,267 | ||
| (iii) Sole power to dispose or to direct the disposition of:
ABG WTT-Ceribell Limited: 0
ABG V-Ceribell Limited: 0
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0
ABG Global Life Science Capital Partners V GP, L.P. : 0
ABG Global Life Science Capital Partners V GP Limited: 0
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0
ABG-WTT Global Life Science Capital Partners GP, L.P.: 0
ABG-WTT Global Life Science Capital Partners GP Limited: 0
ABG Management Ltd.: 0
Ally Bridge Group (PE) LLC: 0
Fan Yu: 0 | ||
| (iv) Shared power to dispose or to direct the disposition of:
ABG WTT-Ceribell Limited: 2,441,267
ABG V-Ceribell Limited: 2,441,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP, L.P.: 2,441,267
ABG Global Life Science Capital Partners V GP Limited: 2,441,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 2,441,267
ABG-WTT Global Life Science Capital Partners GP, L.P.: 2,441,267
ABG-WTT Global Life Science Capital Partners GP Limited: 2,441,267
ABG Management Ltd.: 2,441,267
Ally Bridge Group (PE) LLC: 2,441,267
Fan Yu: 2,441,267 | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
Not Applicable
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit Information
|
[Exhibit A - Joint Filing Agreement] |